<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Definition and criteria for chronic kidney disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Definition and criteria for chronic kidney disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Definition and criteria for chronic kidney disease</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Definition:</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="2">Chronic kidney disease is defined based on the presence of either kidney damage or decreased kidney function for three or more months, irrespective of cause.</td> </tr> <tr> <td class="subtitle1">Criteria</td> <td class="subtitle1">Comment</td> </tr> <tr class="divider_bottom"> <td>Duration ≥3 months, based on documentation or inference</td> <td>Duration is necessary to distinguish chronic from acute kidney diseases. <ul class="decimal_heading"> <li>Clinical evaluation can often suggest duration </li> <li>Documentation of duration is usually not available in epidemiologic studies </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Glomerular filtration rate (GFR) &lt;60 mL/min/1.73 m<sup>2</sup></td> <td>GFR is the best overall index of kidney function in health and disease. <ul class="decimal_heading"> <li>The normal GFR in young adults is approximately 125 mL/min/1.73 m<sup>2</sup>; GFR &lt;15 mL/min/1.73 m<sup>2</sup> is defined as kidney failure </li> <li>Decreased GFR can be detected by current estimating equations for GFR based on serum creatinine (estimated GFR) but not by serum creatinine alone </li> <li>Decreased estimated GFR can be confirmed by measured GFR<span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">, measured creatinine clearance, or estimated GFR using cystatin C</span></li> </ul> </td> </tr> <tr> <td rowspan="5">Kidney damage, as defined by structural abnormalities or functional abnormalities other than decreased GFR</td> <td>Pathologic abnormalities (examples). Cause is based on underlying illness and pathology. Markers of kidney damage may reflect pathology. <ul class="decimal_heading"> <li>Glomerular diseases (diabetes, autoimmune diseases, systemic infections, drugs, neoplasia) </li> <li>Vascular diseases (atherosclerosis, hypertension, ischemia, vasculitis, thrombotic microangiopathy) </li> <li>Tubulointerstitial diseases (urinary tract infections, stones, obstruction, drug toxicity) </li> <li>Cystic disease (polycystic kidney disease) </li> </ul> </td> </tr> <tr> <td>History of kidney transplantation. In addition to pathologic abnormalities observed in native kidneys, common pathologic abnormalities include the following: <ul class="decimal_heading"> <li>Chronic allograft nephropathy (non-specific findings of tubular atrophy, interstitial fibrosis, vascular and glomerular sclerosis) </li> <li>Rejection </li> <li>Drug toxicity (calcineurin inhibitors) </li> <li>BK virus nephropathy </li> <li>Recurrent disease (glomerular disease, oxalosis, Fabry disease) </li> </ul> </td> </tr> <tr> <td>Albuminuria as a marker of kidney damage (increased glomerular permeability, urine albumin-to-creatinine ratio [ACR] &gt;30 mg/g).* <ul class="decimal_heading"> <li>The normal urine ACR in young adults is &lt;10 mg/g. Urine ACR categories 10-29, 30-300 and &gt;300 mg are termed "mildly increased, moderately increased, and severely increased" respectively. Urine ACR &gt;2200 mg/g is accompanied by signs and symptoms of nephrotic syndrome (low serum albumin, edema and high serum cholesterol). </li> <li>Threshold value corresponds approximately to urine dipstick values of trace or 1+, depending on urine concentration </li> <li>High urine ACR can be confirmed by urine albumin excretion in a timed urine collection </li> </ul> </td> </tr> <tr> <td>Urinary sediment abnormalities as markers of kidney damage, for example:  <ul class="decimal_heading"> <li>RBC casts in proliferative glomerulonephritis </li> <li>WBC casts in pyelonephritis or interstitial nephritis </li> <li>Oval fat bodies or fatty casts in diseases with proteinuria </li> <li>Granular casts and renal tubular epithelial cells in many parenchymal diseases (non-specific) </li> </ul> </td> </tr> <tr> <td>Imaging abnormalities as markers of kidney damage (ultrasound, computed tomography and magnetic resonance imaging with or without contrast, isotope scans, angiography). <ul class="decimal_heading"> <li>Polycystic kidneys </li> <li>Hydronephrosis due to obstruction </li> <li>Cortical scarring due to infarcts, pyelonephritis or vesicoureteral reflux </li> <li>Renal masses or enlarged kidneys due to infiltrative diseases </li> <li>Renal artery stenosis </li> <li>Small and echogenic kidneys (common in later stages of CKD due to many parenchymal diseases) </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">* Albumin-to-creatinine ratio (ACR) conversion factor 1.0 mg/g = 0.113 mg/mmol.</div><div class="graphic_reference">Reproduced from: Levey A, Coresh J. Chronic kidney disease. Lancet 2011. DOI: 10.1016/S0140-6736(11)60178-5. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 80632 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
